{
    "clinical_study": {
        "@rank": "26794", 
        "arm_group": {
            "arm_group_label": "LCL161", 
            "arm_group_type": "Experimental", 
            "description": "Dose escalation part: Eligible patients will start to receive oral LCL161 once a week and will receive weekly paclitaxel, at 80 mg/m2 intravenous infusion over 1 hour, in combination with LCL161 from cycle 2. Dose expansion part: Eligible patients will receive oral LCL161 at the maximum tolerated dose and/or recommended dose in combination with weekly paclitaxel, at 80 mg/m2 intravenous infusion over 1 hour from cycle 1."
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate safety and tolerability to estimate the maximum tolerated dose\n      and/or recommended dose of oral LCL161 in Japanese patients with advanced solid tumors."
        }, 
        "brief_title": "Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Neoplasms", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. Patients with a histologically or cytologically confirmed diagnosis of a solid tumor\n             for which no further effective standard treatment is available.\n\n          2. ECOG performance status 0-1.\n\n          3. Patients must have recovered from all toxicities related to their previous treatment.\n\n        Exclusion criteria:\n\n          1. Unresolved nausea, vomiting, diarrhea or peripheral neuropathy CTCAE grade >1.\n\n          2. History of or current interstitial lung disease or autoimmune disease.\n\n          3. History of or current impaired cardiac function or clinically significant cardiac\n             diseases.\n\n          4. Women of child-bearing potential, unless they are using highly effective methods of\n             contraception.\n\n        Other protocol-defined inclusion/exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01968915", 
            "org_study_id": "CLCL161A1102"
        }, 
        "intervention": [
            {
                "arm_group_label": "LCL161", 
                "description": "Patients will receive oral LCL161 once a week until unacceptable toxicity, disease progression and/or withdrawal of consent.", 
                "intervention_name": "LCL161", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LCL161", 
                "description": "Patients will receive weekly paclitaxel as intravenous infusion over 1 hour in combination with LCL161, from cycle 2 in dose escalation part or from the first cycle in dose expansion part, and will continue it until unacceptable toxicity, disease progression and/or withdrawal of consent.", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "LCL161, Paclitaxel, Japanese patient, Neoplasms", 
        "lastchanged_date": "January 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Nagoya-city", 
                        "country": "Japan", 
                        "state": "Aichi", 
                        "zip": "466-8560"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kobe-city", 
                        "country": "Japan", 
                        "state": "Hyogo", 
                        "zip": "650-0017"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Study of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+81337978748"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceutical and Medical Devices Agency (PMDA)"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Frequency of dose limiting toxicities as a function of LCL161 during first cycle", 
                "safety_issue": "Yes", 
                "time_frame": "First cycle (21 days)"
            }, 
            {
                "description": "Type and frequency of adverse events of oral LCL161 when administered in combination with weekly paclitaxel", 
                "measure": "Adverse events of oral LCL161", 
                "safety_issue": "Yes", 
                "time_frame": "From informed consent until 28 days after end of treatment (end of treatment visit occurs within 7 days after the determination of study discontinuation)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01968915"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Type and frequency of adverse events of oral LCL161", 
                "measure": "Adverse events of oral LCL161", 
                "safety_issue": "Yes", 
                "time_frame": "From informed consent until 28 days after end of treatment (end of treatment visit occurs within 7 days after the determination of study discontinuation)"
            }, 
            {
                "measure": "LCL161 plasma concentration and derived pharmacokinetic parameters", 
                "safety_issue": "No", 
                "time_frame": "From first cycle and up to 3 cycle (each cycle is 21-day period)"
            }, 
            {
                "measure": "Paclitaxel plasma concentration and derived pharmacokinetic parameters", 
                "safety_issue": "No", 
                "time_frame": "From first cycle of combination and up to 2 cycle (each cycle is 21-day period)"
            }, 
            {
                "measure": "Tumor response according to RECIST 1.1", 
                "safety_issue": "No", 
                "time_frame": "Every 2 cycles for first 8 cycles, then every 3 cycles and until end of treatment (each cycle is 21-day period and end of treatment visit occurs within 7 days after the determination of study discontinuation)"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}